Anti-Human CD20 Therapeutic Antibody (Ibritumomab)
Recombinant monoclonal antibody to Human CD20. Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma, a lymphoproliferative disorder and thus affects the lymphatic system. The drug uses the monoclonal mouse IgG1 antibody ibritumomab (pronounced as < ih bri TYOO mo mab >) in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-001 |
| Pricing | Inquiry |
| Host | Mouse |
| Target | CD20 |
| Species Reactivity | Human |
| Type | IgG1 - kappa |
| Applications | ELISA, IP, FC, FuncS, IF, Neut |
| Storage | Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage. |